VSTM – Verastem, Inc.
Verastem, Inc.VSTM
$7.23Name : Verastem, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $544,562,176.00
EPSttm : -4.28
Verastem, Inc.
$7.23
6.35%$0.49Float Short %
25.64
Margin Of Safety %
Put/Call OI Ratio
0.17
EPS Next Q Diff
0.81
EPS Last/This Y
0.94
EPS This/Next Y
1.06
Price
7.24
Target Price
16
Analyst Recom
1
Performance Q
-19.58
Relative Volume
0.56
Beta
0.44
Ticker: VSTM
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-08 | VSTM | 10.26 | 0.43 | 1.12 | 22436 |
| 2025-12-09 | VSTM | 10.1 | 0.44 | 0.68 | 22522 |
| 2025-12-10 | VSTM | 9.99 | 0.44 | 8.42 | 22565 |
| 2025-12-11 | VSTM | 9.43 | 0.44 | 0.24 | 22526 |
| 2025-12-12 | VSTM | 9.61 | 0.44 | 0.28 | 22747 |
| 2025-12-15 | VSTM | 9.26 | 0.44 | 3.80 | 22944 |
| 2025-12-16 | VSTM | 8.63 | 0.45 | 2.17 | 23069 |
| 2025-12-17 | VSTM | 7.95 | 0.46 | 2.61 | 23367 |
| 2025-12-18 | VSTM | 7.74 | 0.47 | 0.30 | 23541 |
| 2025-12-19 | VSTM | 7.76 | 0.45 | 0.12 | 23474 |
| 2025-12-22 | VSTM | 7.89 | 0.09 | 0.50 | 8641 |
| 2025-12-23 | VSTM | 7.93 | 0.13 | 0.81 | 9586 |
| 2025-12-26 | VSTM | 8.08 | 0.15 | 0.03 | 9834 |
| 2025-12-29 | VSTM | 7.75 | 0.14 | 0.02 | 9850 |
| 2025-12-30 | VSTM | 7.54 | 0.15 | 2.32 | 9806 |
| 2025-12-31 | VSTM | 7.73 | 0.16 | 0.00 | 9897 |
| 2026-01-02 | VSTM | 7.24 | 0.17 | 0.02 | 10029 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-08 | VSTM | 10.25 | 20.0 | - | -2.73 |
| 2025-12-09 | VSTM | 10.12 | 20.0 | - | -2.73 |
| 2025-12-10 | VSTM | 9.98 | 20.0 | - | -2.73 |
| 2025-12-11 | VSTM | 9.44 | 20.0 | - | -2.73 |
| 2025-12-12 | VSTM | 9.61 | 20.0 | - | -2.73 |
| 2025-12-15 | VSTM | 9.27 | 20.0 | - | -2.73 |
| 2025-12-16 | VSTM | 9.27 | 20.0 | - | -2.73 |
| 2025-12-17 | VSTM | 7.95 | 20.0 | - | -2.73 |
| 2025-12-18 | VSTM | 7.74 | 20.0 | - | -2.73 |
| 2025-12-19 | VSTM | 7.76 | 20.0 | - | -2.73 |
| 2025-12-22 | VSTM | 7.86 | 20.0 | - | -2.73 |
| 2025-12-23 | VSTM | 7.89 | 20.0 | - | -2.73 |
| 2025-12-26 | VSTM | 8.06 | 20.0 | - | -2.73 |
| 2025-12-29 | VSTM | 7.76 | 20.0 | - | -2.73 |
| 2025-12-30 | VSTM | 7.54 | 20.0 | - | -2.73 |
| 2025-12-31 | VSTM | 7.73 | 20.0 | - | -2.73 |
| 2026-01-02 | VSTM | 7.24 | 20.0 | - | -2.73 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-08 | VSTM | -0.69 | 2.74 | 29.36 |
| 2025-12-09 | VSTM | -0.75 | 2.74 | 29.36 |
| 2025-12-10 | VSTM | -0.75 | 2.74 | 28.22 |
| 2025-12-11 | VSTM | -0.75 | 2.74 | 28.21 |
| 2025-12-12 | VSTM | -0.75 | 2.74 | 28.21 |
| 2025-12-15 | VSTM | -0.79 | 2.74 | 28.21 |
| 2025-12-16 | VSTM | -0.79 | 2.74 | 28.21 |
| 2025-12-17 | VSTM | -0.79 | 2.74 | 28.21 |
| 2025-12-18 | VSTM | -0.80 | 2.74 | 28.21 |
| 2025-12-19 | VSTM | -0.80 | 2.74 | 28.21 |
| 2025-12-22 | VSTM | -0.79 | 2.74 | 28.21 |
| 2025-12-23 | VSTM | -0.79 | 2.74 | 28.21 |
| 2025-12-26 | VSTM | -0.57 | 2.74 | 25.64 |
| 2025-12-29 | VSTM | -0.57 | 2.74 | 25.64 |
| 2025-12-30 | VSTM | -0.57 | 2.74 | 25.64 |
| 2025-12-31 | VSTM | -0.57 | 2.74 | 25.64 |
| 2026-01-02 | VSTM | -0.57 | 2.74 | 25.64 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.35
Avg. EPS Est. Current Quarter
-0.48
Avg. EPS Est. Next Quarter
-0.54
Insider Transactions
-0.57
Institutional Transactions
2.74
Beta
0.44
Average Sales Estimate Current Quarter
16
Average Sales Estimate Next Quarter
16
Fair Value
Quality Score
5
Growth Score
46
Sentiment Score
42
Actual DrawDown %
87.8
Max Drawdown 5-Year %
-96.2
Target Price
16
P/E
Forward P/E
PEG
P/S
40.7
P/B
P/Free Cash Flow
EPS
-4.26
Average EPS Est. Cur. Y
-2.73
EPS Next Y. (Est.)
-1.67
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-1802.12
Relative Volume
0.56
Return on Equity vs Sector %
Return on Equity vs Industry %
EPS 1 7Days Diff
-0.3
EPS 1 30Days Diff
-0.29
EBIT Estimation
Verastem, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 78
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
stock quote shares VSTM – Verastem, Inc. Stock Price stock today
news today VSTM – Verastem, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VSTM – Verastem, Inc. yahoo finance google finance
stock history VSTM – Verastem, Inc. invest stock market
stock prices VSTM premarket after hours
ticker VSTM fair value insiders trading